Pfizer Inc. (PFE)
Pfizer scraps daily weight loss pill after liver injury in one patient
Pfizer said it would end development of its experimental daily weight loss pill after a patient experienced a liver injury that was potentially caused by the drug in a trial. The patient's liver enzymes "recovered rapidly" after they stopped taking the pill, which is an oral GLP-1 drug called danuglipron.
Pfizer is halting development of its experimental weight-loss pill, as the booming obesity drug market remains out of reach for the drug giant
Danuglipron was the latest drug investors were hinging hope on to enter the obesity market.
Pfizer Halts Development of New Weight-Loss Drug
The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.
1 Deeply Undervalued Stock to Buy in the Market Correction
Pfizer's (PFE 1.39%) shares have been southbound for the better part of three years, partly because it was unable to repeat its incredible financial performance during the early pandemic years. However, the company took another dive this year along with the broader market; President Donald Trump's trade wars are leaving few stocks completely unscathed.
Pfizer (PFE) Advances But Underperforms Market: Key Facts
Pfizer (PFE) closed the most recent trading day at $21.91, moving +1.48% from the previous trading session.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pfizer Stock Falls to New 52-Week Low: Should You Buy the Dip?
PFE stock is likely to be a great pick for value investors, considering its cheap valuation, as well as for income investors due to its sky-high dividend yield.
Pfizer: Anticipating A Game-Changer Soon
I reaffirm my Buy rating on Pfizer due to expected promising updates on danuglipron and strong capital efficiency metrics, despite the recent stock pullback. Pfizer's management is expected to announce danuglipron updates soon, potentially boosting investor sentiment and stock performance. Pfizer's cost reduction programs and revenue growth targets for CY25 remain on track, with EPS projected to more than double.
Pfizer: Best-In-Class Dividend Yield Together With Dirt Cheap Valuation
Pfizer's 7.5% dividend yield is safe due to revenue growth, cost efficiency, and a stronger balance sheet, making it a strong buy. Pfizer's innovation in R&D, including AI partnerships and new drug approvals, promises long-term market cap growth and a competitive edge. Defensive stocks like Pfizer are attractive amid market volatility, with the pharmaceutical sector being less vulnerable to economic cycles.
Is Pfizer (PFE) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Better Beaten-Down Stock to Buy: Pfizer Vs. Moderna
In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field: Pfizer (PFE 0.77%) and Moderna (MRNA 2.21%). These two vaccine makers made small fortunes thanks to their work in this space.
Is Pfizer Stock a Buy?
Pfizer's (PFE 0.77%) share price has fallen more than the S&P 500 so far this year. The big pharma stock is nearly 60% below its high set in late 2022.
